Literature DB >> 3018228

Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo.

K M Kumor, C A Haertzen, R E Johnson, T Kocher, D Jasinski.   

Abstract

The activity of ketocyclazocine, a putative kappa opioid receptor agonist, was studied and compared with that of morphine, a mu opioid receptor agonist, and cyclazocine, a putative kappa and sigma opioid receptor agonist, vs. placebo in 10 drug abusers. The measures included vital signs and pupil measurements, established and new observer- and subject-completed psychopharmacologic questionnaires and several methods of drug discrimination. The results indicate that ketocyclazocine is different from morphine-like agonists in that it produces only minimal miosis and lacks euphoriant action. It causes a dysphoric state and was clearly discriminated from morphine. The dysphoria and pattern of responses was similar to cyclazocine though ketocyclazocine was discriminated from cyclazocine. This is consistent with the concept that morphine and ketocyclazocine have separate modes of primary activity. The similarity between ketocyclazocine and cyclazocine obscures the assignment of particular drug effects to activity at the kappa receptor.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3018228

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  24 in total

1.  Reduced alcohol consumption in mice lacking preprodynorphin.

Authors:  Yuri A Blednov; Danielle Walker; Marni Martinez; R Adron Harris
Journal:  Alcohol       Date:  2006-10       Impact factor: 2.405

2.  Sex differences in the potency of kappa opioids and mixed-action opioids administered systemically and at the site of inflammation against capsaicin-induced hyperalgesia in rats.

Authors:  Lisa M Lomas; Andrew C Barrett; Jolan M Terner; Donald T Lysle; Mitchell J Picker
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

3.  Effects of butorphanol on morphine-induced itch and analgesia in primates.

Authors:  Heeseung Lee; Norah N Naughton; James H Woods; Mei-Chuan Ko
Journal:  Anesthesiology       Date:  2007-09       Impact factor: 7.892

4.  Evaluation of the effects of opioid agonists and antagonists under a delayed matching-to-sample procedure in pigeons.

Authors:  M Picker; C A Massie; L A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Effects of kappa opioid receptor agonists on fentanyl vs. food choice in male and female rats: contingent vs. non-contingent administration.

Authors:  E Andrew Townsend
Journal:  Psychopharmacology (Berl)       Date:  2021-01-06       Impact factor: 4.530

Review 6.  Neoclerodanes as atypical opioid receptor ligands.

Authors:  Thomas E Prisinzano
Journal:  J Med Chem       Date:  2013-04-18       Impact factor: 7.446

7.  Trends in drug discrimination research analysed with a cross-indexed bibliography, 1984-1987.

Authors:  I P Stolerman; F Rasul; P J Shine
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 8.  Kappa opioids and the modulation of pain.

Authors:  Bronwyn Kivell; Thomas E Prisinzano
Journal:  Psychopharmacology (Berl)       Date:  2010-04-07       Impact factor: 4.530

9.  Effects of the psychotomimetic benzomorphan N-allylnormetazocine (SKF 10,047) on prepulse inhibition of startle in mice.

Authors:  Adam L Halberstadt; James Hyun; Michael A Ruderman; Susan B Powell
Journal:  Pharmacol Biochem Behav       Date:  2016-05-26       Impact factor: 3.533

Review 10.  Neuraxial opioid-induced itch and its pharmacological antagonism.

Authors:  Mei-Chuan Ko
Journal:  Handb Exp Pharmacol       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.